ES2982270T3 - Constructos y procedimientos de terapia génica para el tratamiento de la pérdida de audición - Google Patents
Constructos y procedimientos de terapia génica para el tratamiento de la pérdida de audición Download PDFInfo
- Publication number
- ES2982270T3 ES2982270T3 ES18768248T ES18768248T ES2982270T3 ES 2982270 T3 ES2982270 T3 ES 2982270T3 ES 18768248 T ES18768248 T ES 18768248T ES 18768248 T ES18768248 T ES 18768248T ES 2982270 T3 ES2982270 T3 ES 2982270T3
- Authority
- ES
- Spain
- Prior art keywords
- hearing loss
- tmprss3
- gene
- hearing
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010011878 Deafness Diseases 0.000 title claims abstract description 157
- 208000016354 hearing loss disease Diseases 0.000 title claims abstract description 156
- 230000010370 hearing loss Effects 0.000 title claims abstract description 134
- 231100000888 hearing loss Toxicity 0.000 title claims abstract description 134
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title abstract description 14
- 238000001415 gene therapy Methods 0.000 title description 28
- 210000002768 hair cell Anatomy 0.000 claims abstract description 79
- 101000798700 Homo sapiens Transmembrane protease serine 3 Proteins 0.000 claims abstract description 68
- 230000035772 mutation Effects 0.000 claims abstract description 62
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 claims abstract description 46
- 101100343697 Homo sapiens LOXHD1 gene Proteins 0.000 claims abstract description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 25
- 150000007523 nucleic acids Chemical group 0.000 claims description 24
- 230000002068 genetic effect Effects 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000013603 viral vector Substances 0.000 claims description 15
- 102000045778 human TMPRSS3 Human genes 0.000 claims description 12
- 102220015155 rs181949335 Human genes 0.000 claims description 10
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 9
- 210000001062 endolymphatic sac Anatomy 0.000 claims description 7
- 238000011830 transgenic mouse model Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims 2
- 210000000262 cochlear duct Anatomy 0.000 claims 2
- 102200098637 rs137852999 Human genes 0.000 claims 2
- 102200098636 rs137853000 Human genes 0.000 claims 2
- 102220015147 rs147231991 Human genes 0.000 claims 2
- 102220238149 rs200090033 Human genes 0.000 claims 2
- 102200098592 rs201632198 Human genes 0.000 claims 2
- 102200098628 rs28939084 Human genes 0.000 claims 2
- 102220054519 rs372526764 Human genes 0.000 claims 2
- 102200098604 rs387906915 Human genes 0.000 claims 2
- 102200098632 rs56264519 Human genes 0.000 claims 2
- 102220054522 rs727503493 Human genes 0.000 claims 2
- 102220054410 rs727504304 Human genes 0.000 claims 2
- 102100023915 Insulin Human genes 0.000 claims 1
- 102220310832 rs1555783543 Human genes 0.000 claims 1
- 102220297961 rs397517376 Human genes 0.000 claims 1
- 102220040455 rs41281202 Human genes 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 63
- 210000003027 ear inner Anatomy 0.000 abstract description 38
- 101001043326 Homo sapiens Lipoxygenase homology domain-containing protein 1 Proteins 0.000 abstract description 30
- 102100021959 Lipoxygenase homology domain-containing protein 1 Human genes 0.000 abstract description 25
- 230000004083 survival effect Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- 238000001476 gene delivery Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 5
- 230000003612 virological effect Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 54
- 102100032454 Transmembrane protease serine 3 Human genes 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 39
- 101100260870 Mus musculus Tmprss3 gene Proteins 0.000 description 29
- 238000010172 mouse model Methods 0.000 description 29
- 238000012360 testing method Methods 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 231100000895 deafness Toxicity 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 239000005090 green fluorescent protein Substances 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 210000001323 spiral ganglion Anatomy 0.000 description 15
- 108091033409 CRISPR Proteins 0.000 description 14
- 241000282412 Homo Species 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 13
- 230000000750 progressive effect Effects 0.000 description 13
- 206010010356 Congenital anomaly Diseases 0.000 description 12
- 210000003477 cochlea Anatomy 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 230000007850 degeneration Effects 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- 238000011813 knockout mouse model Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000010354 CRISPR gene editing Methods 0.000 description 7
- 206010011891 Deafness neurosensory Diseases 0.000 description 7
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 7
- 230000006727 cell loss Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 7
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 7
- 239000013607 AAV vector Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241001362551 Samba Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000000883 ear external Anatomy 0.000 description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 4
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 4
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 4
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 208000033022 autosomal recessive nonsyndromic hearing loss 77 Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 102000055368 human LOXHD1 Human genes 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- FUSGACRLAFQQRL-UHFFFAOYSA-N N-Ethyl-N-nitrosourea Chemical compound CCN(N=O)C(N)=O FUSGACRLAFQQRL-UHFFFAOYSA-N 0.000 description 3
- 101150065274 Tmc gene Proteins 0.000 description 3
- 101150045685 Tmprss3 gene Proteins 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 201000006140 autosomal recessive nonsyndromic deafness 77 Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000012496 juvenile nasopharyngeal angiofibroma Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000006790 nonsyndromic deafness Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000009118 salvage therapy Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002480 semicircular canal Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000003582 temporal bone Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000001720 vestibular Effects 0.000 description 3
- 101150084750 1 gene Proteins 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000000781 Conductive Hearing Loss Diseases 0.000 description 2
- 206010010280 Conductive deafness Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 101710136259 E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 101100260869 Homo sapiens TMPRSS3 gene Proteins 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000023563 conductive hearing loss disease Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003060 endolymph Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000012074 hearing test Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000067 inner hair cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000002985 organ of corti Anatomy 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 210000004049 perilymph Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 102100040191 Alpha-tectorin Human genes 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101100425646 Caenorhabditis elegans tmc-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000023914 Central Auditory disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- 102100031060 Clarin-1 Human genes 0.000 description 1
- 101710093463 Clarin-1 Proteins 0.000 description 1
- 208000026091 Congenital hearing disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150083557 Ear gene Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 208000032041 Hearing impaired Diseases 0.000 description 1
- 101000889766 Homo sapiens Alpha-tectorin Proteins 0.000 description 1
- 101100180047 Homo sapiens ISL1 gene Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 101150010734 Loxhd1 gene Proteins 0.000 description 1
- 208000008719 Mixed Conductive-Sensorineural Hearing Loss Diseases 0.000 description 1
- 101100343698 Mus musculus Loxhd1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101150086693 Slc17a8 gene Proteins 0.000 description 1
- 108010004408 TRPP Cation Channels Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102100038033 Vesicular glutamate transporter 3 Human genes 0.000 description 1
- 102100038102 Whirlin Human genes 0.000 description 1
- 101710155241 Whirlin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019467 X-linked deafness Diseases 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003030 auditory receptor cell Anatomy 0.000 description 1
- 201000005823 autosomal dominant nonsyndromic deafness 12 Diseases 0.000 description 1
- 208000034083 autosomal dominant nonsyndromic hearing loss 12 Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000010336 brain pathway Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000004307 hair cells vestibular Anatomy 0.000 description 1
- 230000008230 hearing development Effects 0.000 description 1
- 238000012071 hearing screening Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000008140 language development Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000012072 newborn hearing screening Methods 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000010255 response to auditory stimulus Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002205 spiral ligament of cochlea Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000645 stria vascularis Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 101150009136 tlcA gene Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000027491 vestibular disease Diseases 0.000 description 1
- 210000000752 vestibulocochlear nerve Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472790P | 2017-03-17 | 2017-03-17 | |
| US201762531522P | 2017-07-12 | 2017-07-12 | |
| PCT/US2018/022873 WO2018170402A1 (en) | 2017-03-17 | 2018-03-16 | Gene therapy constructs and methods for treatment of hearing loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2982270T3 true ES2982270T3 (es) | 2024-10-15 |
Family
ID=63522674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18768248T Active ES2982270T3 (es) | 2017-03-17 | 2018-03-16 | Constructos y procedimientos de terapia génica para el tratamiento de la pérdida de audición |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200248203A1 (https=) |
| EP (1) | EP3595634B1 (https=) |
| JP (1) | JP2020509786A (https=) |
| KR (1) | KR102752457B1 (https=) |
| CN (1) | CN110709060A (https=) |
| BR (1) | BR112019019367A2 (https=) |
| CA (1) | CA3054941A1 (https=) |
| ES (1) | ES2982270T3 (https=) |
| IL (1) | IL268912B2 (https=) |
| WO (1) | WO2018170402A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12391936B2 (en) | 2017-03-17 | 2025-08-19 | Rescue Hearing, Inc. | Gene therapy systems and related methods for treatment of hearing loss |
| WO2020077295A1 (en) | 2018-10-11 | 2020-04-16 | Decibel Therapeutics, Inc. | Aav1 vectors and uses thereof for treatment of otic indications |
| CN112442528B (zh) * | 2019-08-30 | 2022-08-12 | 深圳华大基因股份有限公司 | Loxhd1基因突变体及其应用 |
| IL295265A (en) * | 2020-02-05 | 2022-10-01 | Rescue Hearing Inc | Gene therapy systems and related methods for treatment of hearing loss |
| EP4008788A1 (en) * | 2020-12-03 | 2022-06-08 | Medizinische Hochschule Hannover | Lentiviral vector technology for inner ear gene therapy |
| CN113584082B (zh) * | 2021-06-22 | 2023-07-25 | 复旦大学附属眼耳鼻喉科医院 | CRISPR/Cas9基因编辑系统及其在制备治疗遗传性感音神经性聋的药物中的应用 |
| CN113215248B (zh) * | 2021-06-25 | 2022-04-22 | 中国人民解放军空军军医大学 | 一种感音神经性耳聋相关的myo15a基因突变检测试剂盒 |
| KR20260026049A (ko) * | 2023-06-15 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 청력 장애에 대한 유전자 치료 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1280923A2 (en) * | 2000-04-28 | 2003-02-05 | Millennium Pharmaceuticals, Inc. | 14094, a human trypsin family member and uses thereof |
| WO2004099779A1 (en) * | 2003-05-05 | 2004-11-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 3 (tmprss3) |
| EP1922410A2 (en) * | 2005-08-15 | 2008-05-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| WO2011075838A1 (en) * | 2009-12-21 | 2011-06-30 | Audigen Inc. | Method of treating or preventing hearing loss |
| US20150050354A1 (en) * | 2012-04-02 | 2015-02-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for the treatment of otic diseases and conditions |
| AU2013293270B2 (en) | 2012-07-25 | 2018-08-16 | Massachusetts Institute Of Technology | Inducible DNA binding proteins and genome perturbation tools and applications thereof |
| WO2015048577A2 (en) | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| CN106232618A (zh) | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| WO2015175642A2 (en) * | 2014-05-13 | 2015-11-19 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a disease |
| US10258697B2 (en) | 2014-10-29 | 2019-04-16 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules in vitro and in vivo |
| SG10201913266UA (en) * | 2015-12-11 | 2020-02-27 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
-
2018
- 2018-03-16 JP JP2020500024A patent/JP2020509786A/ja active Pending
- 2018-03-16 US US16/488,103 patent/US20200248203A1/en active Pending
- 2018-03-16 CA CA3054941A patent/CA3054941A1/en active Pending
- 2018-03-16 BR BR112019019367A patent/BR112019019367A2/pt unknown
- 2018-03-16 WO PCT/US2018/022873 patent/WO2018170402A1/en not_active Ceased
- 2018-03-16 CN CN201880028001.3A patent/CN110709060A/zh active Pending
- 2018-03-16 KR KR1020197030012A patent/KR102752457B1/ko active Active
- 2018-03-16 IL IL268912A patent/IL268912B2/en unknown
- 2018-03-16 EP EP18768248.9A patent/EP3595634B1/en active Active
- 2018-03-16 ES ES18768248T patent/ES2982270T3/es active Active
-
2019
- 2019-12-24 US US16/726,495 patent/US20200114023A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3595634A4 (en) | 2020-11-04 |
| IL268912A (en) | 2019-10-31 |
| EP3595634B1 (en) | 2024-03-27 |
| IL268912B2 (en) | 2024-11-01 |
| IL268912B1 (en) | 2024-07-01 |
| CA3054941A1 (en) | 2018-09-20 |
| US20200114023A1 (en) | 2020-04-16 |
| US20200248203A1 (en) | 2020-08-06 |
| KR20190131052A (ko) | 2019-11-25 |
| JP2020509786A (ja) | 2020-04-02 |
| CN110709060A (zh) | 2020-01-17 |
| KR102752457B1 (ko) | 2025-01-09 |
| EP3595634A1 (en) | 2020-01-22 |
| BR112019019367A2 (pt) | 2020-04-14 |
| WO2018170402A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2982270T3 (es) | Constructos y procedimientos de terapia génica para el tratamiento de la pérdida de audición | |
| ES2960880T3 (es) | Terapia génica mediada por AAV que restaura el gen de la otoferlina | |
| US20230405085A1 (en) | Prevention and/or treatment of hearing loss or impairment | |
| CN116236591B (zh) | 用于将核酸递送至耳蜗和前庭细胞的材料和方法 | |
| Zhang et al. | Preclinical evaluation of the efficacy and safety of AAV1-hOTOF in mice and nonhuman primates | |
| BR112020016919A2 (pt) | Composições e métodos para tratamento da deficiência auditiva não associada à idade em um sujeito humano | |
| Du et al. | Rescue of auditory function by a single administration of AAV-TMPRSS3 gene therapy in aged mice of human recessive deafness DFNB8 | |
| WO2025040112A1 (zh) | 一种表达全长耳畸蛋白的双aav载体系统及其应用 | |
| CN113840915A (zh) | 腺相关病毒及其用于内耳疗法的用途 | |
| JP2024534991A (ja) | オトフェリンのアイソフォーム５をコードする二重組換えａａｖ８ベクター系およびその使用 | |
| Duhon et al. | Gene therapy advancements for the treatment of acquired and hereditary hearing loss | |
| Kanzaki et al. | Sendai virus vector-mediated transgene expression in the cochlea in vivo | |
| KR20220137652A (ko) | 청력 손실 치료를 위한 유전자 요법 시스템 및 관련 방법 | |
| US12391936B2 (en) | Gene therapy systems and related methods for treatment of hearing loss | |
| HK40014702A (en) | Gene therapy constructs and methods for treatment of hearing loss | |
| KR20250027280A (ko) | 인간 대상체에서 연령-무관 청각 장애를 치료하기 위한 조성물 및 방법 | |
| TW202532649A (zh) | 用於治療具有缺陷耳畸蛋白基因之人類個體之聽力損失的組合物及方法 | |
| CN118215508A (zh) | 编码耳畸蛋白同工型5的双重组aav8载体系统及其用途 | |
| HK40003977A (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |